title: [Rivaroxaban versus standard of care in venous thromboembolism prevention following hip or knee arthroplasty in daily clinical practice (Spanish data from the international study XAMOS)].
abstract: OBJECTIVE
  To analyse the effectiveness and safety of rivaroxaban vs. standard treatment (ST) in the prevention of venous thromboembolism after hip or knee replacement in daily clinical practice in Spain.
  
  
  METHODS
  A sub-analysis of the Spanish data in the XAMOS international observational study that included patients>18 years who received 10mg o.d. rivaroxaban or ST.
  
  
  RESULTS
  up to 3 months after surgery.
  
  
  METHODS
  incidence of symptomatic/asymptomatic thromboembolic events, bleeding, mortality, and other adverse events;
  
  
  RESULTS
  use of health resources and satisfaction after hospital discharge.
  
  
  RESULTS
  Of the total 801 patients included, 410 received rivaroxaban and 391 ST (64.7% heparin, 24.0% fondaparinux, 11% dabigatran). The incidence of symptomatic thromboembolic events and major bleeding was similar in both groups (0.2% vs. 0.8% wit ST and 0.7% vs. 1.3% with ST [EMA criteria]/0.0% vs. 0.3% with ST [RECORD criteria]). The adverse events incidence associated with the drug was significantly higher rivaroxaban (overall: 4.4% vs. 0.8% with ST, P=.001; serious: 1.5% vs. 0.0% with ST, P=.03). The rivaroxaban used less health resources after discharge, and the majority considered the tolerability as «very good« and the treatment as «very comfortable».
  
  
  CONCLUSIONS
  Rivaroxaban is at least as effective as ST in the prevention of venous thromboembolism prevention in daily clinical practice, with a similar incidence of haemorrhages. It provides greater satisfaction/comfort, and less health resources after discharge. These results should be interpreted taking into account the limitations inherent in observational studies.
authors.affiliation: Departamento de Cirugía Ortopédica y Traumatología, Hospital Germans Trias i Pujol, Badalona, Barcelona, España. Electronic address: xgranero.germanstrias@gencat.cat.
authors.forename: J
authors.initials: J
authors.lastname: Granero
authors.affiliation: Departamento de Cirugía Ortopédica y Traumatología, Clínica Universitaria de Navarra, Pamplona, España.
authors.forename: P
authors.initials: P
authors.lastname: Díaz de Rada
authors.affiliation: Departamento de Cirugía Ortopédica y Traumatología, Hospital Clínic i Provincial, Barcelona, España.
authors.forename: L M
authors.initials: LM
authors.lastname: Lozano
authors.affiliation: Departamento de Cirugía Ortopédica y Traumatología, Hospital de Alcorcón, Alcorcón, Madrid, España.
authors.forename: J
authors.initials: J
authors.lastname: Martínez
authors.affiliation: Departamento de Cirugía Ortopédica y Traumatología. Hospital Miguel Servet, Zaragoza, España.
authors.forename: A
authors.initials: A
authors.lastname: Herrera
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019644:Arthroplasty, Replacement, Hip; D019645:Arthroplasty, Replacement, Knee; D004359:Drug Therapy, Combination; D065427:Factor Xa Inhibitors / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology / Q000517:prevention & control*; D011446:Prospective Studies; D000069552:Rivaroxaban / Q000627:therapeutic use*; D013030:Spain; D059039:Standard of Care; D016896:Treatment Outcome; D054556:Venous Thromboembolism / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*
chemical_list: D065427:Factor Xa Inhibitors; D000069552:Rivaroxaban
keywords: Arthroplasty; Artroplastia; Bleeding; Hip replacement; Knee replacement; Profilaxis; Prophylaxis; Reemplazo cadera; Reemplazo rodilla; Rivaroxaban; Sangrado; Thromboembolism; Tromboembolismo